Search Results
505 results found-
Should you get both vaccinations? Yes, says an infectious disease doctor with the U.S. National Foundation for Infectious Diseases.
https://www.csl.com/we-are-csl/vita-original-stories/2021/protecting-yourself-from-covid-19-and-influenza -
CSL presents the World of Promise podcast series, focused on the promise of biotechnology.
https://www.csl.com/we-are-csl/csl-podcasts -
Since the COVID-19 pandemic, there has been a significant drop in influenza immunization rates and high levels of influenza-related illness, underscoring that flu is an ongoing threat.
https://newsroom.csl.com/2023-07-17-CSL-Seqirus-Begins-Shipping-Portfolio-of-Innovative-Influenza-Vaccines-for-the-2023-24-U-S-Season -
From April 24-30, public health officials raise awareness about the protection vaccines provide and their potential to improve global health. This year, the World Health Organization (WHO) celebrates 50 years of its Expanded Programme on Immunization.
https://www.csl.com/we-are-csl/vita-original-stories/2024/world-immunization-week-2024 -
1 Additionally, enhanced vaccines are projected to further reduce the strain on hospitals and intensive care units by 10-15%, supporting bed availability during a potential COVID-19 endemic wave.
https://newsroom.csl.com/2023-09-18-CSL-Seqirus-Shares-Data-Demonstrating-the-Potential-for-Influenza-Vaccination-to-Reduce-the-Burden-on-Healthcare-Resources -
2 During the COVID-19 pandemic, there have been over 95 million confirmed cases of the disease and over 1 million deaths in the U.S. 3 The Centers for Disease Control and Prevention (CDC) recommends COVID-19 vaccination for everyone ages six months and older in the U.S. for the prevention of COVID-19.
https://newsroom.csl.com/2022-12-12-CSL-Announces-Closing-of-Global-Collaboration-and-Licensing-Agreement-with-Arcturus-Therapeutics -
It has developed a COVID-19 vaccine candidate and has recently reported results from a large Phase III vaccine efficacy study, meeting its primary and secondary endpoints of prevention of infection and severe disease with a favorable safety and tolerability profile. "
https://newsroom.csl.com/2022-11-01-CSL-Enters-Licensing-Agreement-with-Arcturus-Therapeutics-for-Next-Generation-mRNA-Vaccine-Technology -
Circulation and Seasonality of Epidemics of Influenza, RSV and Other Respiratory Viruses Before, During, and After the COVID-19 Pandemic:
https://newsroom.csl.com/2023-09-15-CSL-Seqirus-to-Present-at-9th-ESWI-Conference-on-the-Burden-of-Influenza-and-Impact-of-Vaccination-on-Public-Health -
CSL's product portfolio focuses on innovation in new products, improved products and manufacturing expertise thereby ensuring our continued growth.
https://www.csl.com/research-and-development/product-pipeline